Generics - AstraZeneca, Respiratory and Pulmonary


Popular Filters

Generic pains for AstraZeneca exacerbated by Indian drugmakers

Generic pains for AstraZeneca exacerbated by Indian drugmakers


Indian generic companies are taking aim at mega blockbusters, and AstraZeneca, the $25.7 billion pharmaceutical…

Asia-PacificAstraZenecaDr Reddy's LaboratoriesFinancialGastro-intestinalsGenericsIndiaMarkets & MarketingNexiumPharmaceuticalPulmicortRanbaxy LaboratoriesRespiratory and PulmonarySymbicortUSAVimovo

US Appeals Court puts temporary stop on sales of generics of AstraZeneca's Pulmicort Respules


Anglo-Swedish drug major AstraZeneca (LSE: AZN) announced last Friday (May 24) that the US Court of Appeals…

ActavisAstraZenecaGenericsLegalMarkets & MarketingNorth AmericaPharmaceuticalPulmicort RespulesRespiratory and Pulmonary

Actavis wins generic Pulmicort Respules case; challenges AbbVie patent


US generic drugs maker Actavis (NYSE: ACT) has confirmed that the US District Court for the District…

AbbVieActavisAndroGelAstraZenecaGenericsMarkets & MarketingMen's HealthNorth AmericaPatentsPulmicort RespulesRegulationRespiratory and Pulmonary

FDA approves first generic copies of Merck & Co's Singulair; and Pulmicort Respules


The US Food and Drug Administration on Friday approved the first generic versions of Singulair (montelukast…

AstraZenecaGenericsMerck & CoMylan LaboratoriesNorth AmericaPulmicort RespulesRegulationRespiratory and PulmonarySandozSingulairTeva Pharmaceutical IndustriesWatson Pharmaceuticals

Back to top